On a disclosed basis, annual revenue went from KRW 154 billion in 2022 to KRW 151.1 billion in 2023 (down 1.9%), KRW 148.3 billion in 2024 (down 1.8%) and KRW 145.9 billion in 2025 (down 1.6%), a three-year consecutive decline from 2023 through 2025, with 2022 the largest year in the 2022 to 2025 span.
Operating profit fell from KRW 9.63 billion in 2022 to KRW 4.03 billion in 2023 (down 58.1%) and KRW 79.26 million in 2024 (down 98.0%), and the company swung to an operating loss of KRW 30.3 billion in 2025.
The operating margin declined from 6.3% in 2022 to 2.7% in 2023 and 0.1% in 2024 before reaching -20.7% in 2025. The company attributed the 2025 decline to a partial revenue drop from drug price cuts and higher cost of sales from recognizing depreciation on the Chungju plant.
The SG&A ratio fell from 54.5% in 2021 to 49.7% in 2024 and 47.8% in 2025, but this did not offset the cost burden. Industry reporting put depreciation at KRW 1.808 billion in Q3 2024 and KRW 22.382 billion in Q3 2025.
Net profit attributable to owners fell from KRW 4.15 billion in 2024 (up 15.8% from 2023 at KRW 3.58 billion) to a net loss of KRW 29.6 billion in 2025, which was also the 2025 net loss including non-controlling interests.
Operating cash flow moved from -KRW 1.44 billion in 2024 to KRW 1.46 billion in 2025, a return to positive. Quarterly revenue went from KRW 37.6 billion in Q3 2025 to KRW 36.1 billion in Q1 2026, the peak, then fell in Q2 2026 to KRW 35.8 billion and in Q3 2026 to KRW 34 billion, a two-quarter decline.
The operating loss has been reported in five straight quarters, from KRW 7.2 billion in Q3 2025 to KRW 9.25 billion in Q3 2026, and the four quarters from Q4 2025 to Q3 2026 add up to a combined net loss attributable to owners of KRW 42.5 billion.
Based on a trade press report citing the first-half filing, first-half 2026 revenue was KRW 71.9 billion, down 3.4% year on year, and the operating loss narrowed to KRW 13.6 billion from KRW 14.9 billion.
The debt-to-equity ratio rose from 95.6% in 2022 to 111.1% in 2025, with total liabilities of KRW 244.8 billion and total equity of KRW 220.3 billion at end-2025.